On the preclinical (early) and clinical stages of experimental model of Parkinson’s disease after administration of 1-methyl-4-phenyl-1,2,3-6-tetrahydropyridine (MPTP) neurotoxin to mice during 5 and 10 weeks was evaluated the toxic effect of MPTP, i.e. the catecholaminesand their metabolites content’s in the heart, receiving the most extensive sympathetic innervation. The obtained data testified to the beginning of the desimpathization of the heart at the preclinical stage of PD and its progression at the clinical stage of the disease.